详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

Design, synthesis, and biological evaluation of quinazoline derivatives as dual HDAC1 and HDAC6 inhibitors for the treatment of cancer.

文献详情

资源类型：

Pubmed体系：

作者：

机构： [1]Pharmaceutical College, Guangxi Medical University, Nanning, Guangxi, China [2]SinoGrain Chengdu Storage Research Institute Co. Ltd [3]State Key Laboratory of Biotherapy, West China Hospital, West China Medical School, Sichuan University, Chengdu, Sichuan, PR China

出处：

DOI：

ISSN：

关键词： cancer dual inhibitors HDAC SAR study

摘要：

Fifty-eight quinazoline-based compounds were designed and synthesized based on the structural optimizations from the lead compound 23bb in an attempt to search for more potent dual HDAC1 and HDAC6 inhibitors. Among them, 32c (HDAC1, IC50 = 31.10 ± 0.37 nM; HDAC6, IC50 = 16.15 ± 0.62 nM) and 32d (HDAC1, IC50 = 37.00 ± 0.24 nM; HDAC6, IC50 = 35.00 ± 0.71 nM) were not only identified as potent dual-acting HDAC1 and HDAC6 inhibitors with over 10-fold selectivity to the other HDACs, but also displayed activities in tubulin acetylation and histone H3 acetylation induction. Importantly, both of them displayed strong antiproliferative activities against various tumor cell lines in vitro with IC50 values less than 40 nM, especially for hematologic tumors cells (U266 and RPMI8226, IC50 < 1 nM), which were even better than 23bb and SAHA. Furthermore, 32c showed a significant tumor growth inhibition (antitumor rate = 63.98%, p < 0.05) in the resistant MCF-7/ADR xenograft model without any obvious body weight changes and abnormal behaviors. Our findings validate that 32c is a potent dual inhibitor of HDAC1/6 that can be an efficacious treatment for breast cancer with Adriamycin resistance. © 2018 John Wiley & Sons A/S.

基金：

语种：

PubmedID：

中科院(CAS)分区：

出版当年[2019]版：

大类 | 4 区医学

小类 | 4 区生化与分子生物学 4 区药物化学

最新[2023]版：

大类 | 4 区医学

小类 | 4 区生化与分子生物学 4 区药物化学

第一作者：

第一作者机构： [1]Pharmaceutical College, Guangxi Medical University, Nanning, Guangxi, China [2]SinoGrain Chengdu Storage Research Institute Co. Ltd

共同第一作者：

通讯作者：

通讯机构： [1]Pharmaceutical College, Guangxi Medical University, Nanning, Guangxi, China [*1]Pharmaceutical College, Guangxi Medical University, Nanning, Guangxi, China

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]Design and Synthesis of Fibroblast Growth Factor Receptor (FGFR) and Histone Deacetylase (HDAC) Dual Inhibitors for the Treatment of Cancer [2]Discovery of spirooxindole-derived small-molecule compounds as novel HDAC/MDM2 dual inhibitors and investigation of their anticancer activity [3]Development of Dual Inhibitors Targeting Epidermal Growth Factor Receptor in Cancer Therapy. [4]Recent Progress on Tubulin Inhibitors with Dual Targeting Capabilities for Cancer Therapy. [5]Dual-target inhibitors of poly (ADP-ribose) polymerase-1 for cancer therapy: Advances, challenges, and opportunities. [6]Novel dual inhibitors targeting CDK4 and VEGFR2 synergistically suppressed cancer progression and angiogenesis. [7]Dual-target inhibitors of indoleamine 2, 3 dioxygenase 1 (Ido1): A promising direction in cancer immunotherapy. [8]Discovery and SAR Study of Quinoxaline-Arylfuran Derivatives as a New Class of Antitumor Agents [9]Targeting EZH2 for cancer therapy: From current progress to novel strategies. [10]Imaging assisted evaluation of antitumor efficacy of a new histone deacetylase inhibitor in the castration-resistant prostate cancer.